US Coverage

Law360 Authority | Deep News & Analysis

Global Coverage

Law360 Pulse | The Business of Law

Mealeys

MLex

POTTER v. VALEANT PHARMACEUTICALS INTERNATIONAL, INC. et al

Track this case

Case overview

Case Number:

3:15-cv-07658

Court:

New Jersey

Nature of Suit:

Securities/Commodities

Multi Party Litigation:

Class Action

Judge:

Michael A. Shipp

Firms

Companies

Government Agencies

Sectors & Industries:

  1. June 01, 2026

    Valeant Investors Should Get Cert. In PwC Fight, Report Says

    A special master recommended Monday that a New Jersey federal judge certify a class of Valeant Pharmaceuticals stockholders looking to hold PwC liable for missing "red flags" that could have caught what they called market manipulation by the pharmaceutical company, rejecting the professional services giant's argument that the lead plaintiff's claims are atypical and "lawyer-driven."

  2. April 22, 2025

    BlackRock Funds Drop Claims In Valeant Stock Suit

    Dozens of BlackRock funds have dropped their claims in multidistrict securities litigation that accused a Bausch Health Cos. Inc. predecessor and others of a market manipulation scheme that caused a stock plummet, according to an order signed Tuesday by a New Jersey federal judge.

  3. June 15, 2023

    PwC Must Face Valeant Investor Suit Over Missed 'Red Flags'

    A New Jersey federal judge has ruled that PwC cannot escape a lawsuit brought by shareholders of Valeant Pharmaceuticals International Inc. because the auditor missed "red flags" that could have caught the pharmaceutical company's alleged market manipulation earlier.

  4. December 22, 2022

    PwC Pins Blame On Valeant In Securities Fraud Suit

    PricewaterhouseCoopers fought back against a special master's refusal to recommend tossing a securities fraud claim brought by investors of the former Valeant Pharmaceuticals International Inc., arguing it is a victim of the fraud, too.

  5. September 21, 2021

    PwC Can't Shed City's Claim In Valeant Securities Suit

    A New Jersey federal judge on Tuesday refused to free PricewaterhouseCoopers from the remainder of a long-running securities lawsuit brought by investors of the former Valeant Pharmaceuticals International Inc., reasoning that an Arizona city and its pension fund met the pleading requirements for its stock-drop claim.

  6. February 12, 2021

    Robbins Geller's Money Experts Clinch $1.2B Valeant Deal

    The landmark $1.21 billion settlement for Valeant investors presented a tricky task of maximizing recovery without driving the financially embattled drug company into insolvency, prompting lead counsel Robbins Geller Rudman & Dowd LLP to heavily mine its in-house experts for help structuring the right deal.

  7. February 02, 2021

    Final OK On $1.2B Valeant Deal Earns Robbins Geller $157M

    A New Jersey federal judge gave final approval on Monday to a $1.2 billion settlement of an investor action against Valeant Pharmaceuticals, landing lead counsel Robbins Geller Rudman & Dowd LLP a hefty payday.

  8. December 16, 2019

    Bausch Will Pay $1.2B To End Valeant-Era Stock Suit

    Bausch Health Cos. Inc. said Monday it will pay $1.2 billion to resolve a proposed securities class action accusing its former leaders of fraudulently inflating its stock when the Canadian company was known as Valeant Pharmaceuticals International Inc.

  9. August 15, 2019

    Judge Says Bid To Nix Valeant Stock-Drop Suit Unnecessary

    A New Jersey federal judge said Thursday that it would be "a waste of judicial resources" to consider Valeant Pharmaceuticals' bid to toss a complaint from an options brokerage that is part of a proposed consolidated class action alleging Valeant fraudulently inflated its stock price, after previously rejecting the brokerage's own escape move.

  10. July 01, 2019

    Valeant Investor Can't Duck Insider Trading Claims

    A New Jersey federal judge rejected an investment company's bid Sunday to dismiss claims that it illegally dumped Valeant stock ahead of revelations about the drugmaker's supposed deceptive sales practices, saying the firm and its CEO can't rely on their continued ownership of stock to avoid the claims.